Indian pharmaceutical major Cipla announced on Friday that it has been granted approval by the Drugs Controller General of India (DCGI) to sell antiviral drug favipiravir to treat mild to moderate COVID-19 patients.
Cipla will sell the drug under the brand name Ciplenza at ₹68 per tablet.
Ciplenza has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology.
Meanwhile, Pune-headquartered Brinton Pharmaceuticals has received Drugs Controller General of India’s (DCGI) approval to sell antiviral drug favipiravir under the brand name ‘Faviton’ for treatment of COVID-19 patients.
The drug will be available in 200 mg tablets and will be sold at ₹59 per tablet. Favipiravir is an effective treatment option in the management of mild-to-moderate COVID-19, Brinton said.
Favipiravir is an off patent, oral antiviral drug, originally discovered by Fuji Pharma in Japan, and has shown promise in clinical trials for the treatment of Covid-19 patients, especially in mild and moderate cases.